华芢生物招股 拟全球发售1764.88万股H股

Core Viewpoint - Huazhong Biopharmaceutical is set to launch an IPO from December 12 to December 17, 2025, aiming to issue 17.6488 million H-shares, with approximately 10% allocated for public offering in Hong Kong and 90% for international offering, including a 15% over-allotment option [1] Group 1: IPO Details - The offering price per share is expected to range from HKD 38.2 to HKD 51, with trading on the Hong Kong Stock Exchange anticipated to commence on December 22, 2025, at 9 AM Hong Kong time [1] - The company was established in 2012 and focuses on developing protein drugs, primarily targeting wound healing therapies [1] Group 2: Product Pipeline - The core product is rhPDGF-BB, with Pro-101-1 for burn treatment and Pro-101-2 for diabetic foot treatment; the company has ten candidate products, seven of which are PDGF candidates [1] Group 3: Use of Proceeds - Assuming a median offering price of HKD 44.60 and no exercise of the over-allotment option, the net proceeds from the global offering are expected to be approximately HKD 709 million [1] - About 61.8% of the proceeds will fund the ongoing clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [1] - Approximately 18.8% will be used to enhance R&D capabilities through equipment purchases [1] - Around 6.3% will support preclinical development of PDGF products outside the core products [1] - About 3.1% will be allocated for preclinical research activities for Mes-201, Oli-101, and Oli-201 [1] - Approximately 10.0% will be reserved for working capital and general corporate purposes [1]